pubmed-article:17308244 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:17308244 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
pubmed-article:17308244 | lifeskim:mentions | umls-concept:C0036043 | lld:lifeskim |
pubmed-article:17308244 | lifeskim:mentions | umls-concept:C0887947 | lld:lifeskim |
pubmed-article:17308244 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
pubmed-article:17308244 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:17308244 | pubmed:dateCreated | 2007-3-2 | lld:pubmed |
pubmed-article:17308244 | pubmed:abstractText | To improve adherence and virologic suppression, we assessed the feasibility and effectiveness of a once-daily regimen of efavirenz with 3 nucleoside reverse transcriptase inhibitors as first-line or second-line highly active antiretroviral therapy in a cohort of HIV-1-infected children. | lld:pubmed |
pubmed-article:17308244 | pubmed:language | eng | lld:pubmed |
pubmed-article:17308244 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:17308244 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:17308244 | pubmed:month | Mar | lld:pubmed |
pubmed-article:17308244 | pubmed:issn | 1098-4275 | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:KuijpersTaco... | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:ScherpbierHen... | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:JurriaansSuza... | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:LangeJoep M... | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:BekkerVincent... | lld:pubmed |
pubmed-article:17308244 | pubmed:author | pubmed-author:PajkrtDasjaD | lld:pubmed |
pubmed-article:17308244 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:17308244 | pubmed:volume | 119 | lld:pubmed |
pubmed-article:17308244 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:17308244 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:17308244 | pubmed:pagination | e705-15 | lld:pubmed |
pubmed-article:17308244 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:meshHeading | pubmed-meshheading:17308244... | lld:pubmed |
pubmed-article:17308244 | pubmed:year | 2007 | lld:pubmed |
pubmed-article:17308244 | pubmed:articleTitle | Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. | lld:pubmed |
pubmed-article:17308244 | pubmed:affiliation | Emma Children's Hospital, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. | lld:pubmed |
pubmed-article:17308244 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:17308244 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17308244 | lld:pubmed |